search
Back to results

A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction (ALPROC)

Primary Purpose

Small Bowel Obstruction

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
algorithm
Sponsored by
Centre Hospitalier Universitaire, Amiens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Small Bowel Obstruction focused on measuring algorithm, procalcitonin, small bowel obstruction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Uncomplicated acute adhesion-related small bowel obstruction (ASBO)
  • Adults
  • Patients able to express consent
  • Signed written informed consent form
  • Covered by national health insurance

Exclusion Criteria:

  • Disease-related criteria:
  • Large bowel obstruction
  • No previous abdominal surgery
  • Signs of peritonitis or strangulation requiring emergency surgery)
  • Obstruction within 4 weeks following previous surgery
  • Ongoing or history of bowel cancer
  • Ongoing or in history of inflammatory bowel disease
  • History of abdominal radiotherapy
  • Active infection
  • Contraindication to contrast-enhanced CT scan
  • Minors
  • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
  • Pregnancy or breastfeeding

Sites / Locations

  • Amiens Universitary HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

algorithm arm

no algorithm arm

Arm Description

Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.

Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.

Outcomes

Primary Outcome Measures

proportion of patients achieving textbook outcome
textbook outcome is defined as patients either correctly operated (ischemia confirmed at operation ± resection) or correctly managed conservatively (no need for unplanned surgery) with no major postoperative complications (Clavien-Dindo≥3) and a medical length of stay<5 days (defined as the time at which the patient is medically eligible for discharge), with no postoperative consultation, rehospitalisation and reoperation within 90 days after randomization.

Secondary Outcome Measures

1-, 3-, 6-, 9-, 12-month recurrence rates
a new episode of adhesion-related small bowel obstruction.
QSH45 (questionnaire for satisfaction of hospitalized patients) score evaluating patient satisfaction at postoperative month 1
Evaluation of patient satisfaction at postoperative month 1. Values of scores are between 0 and 100. 0 is the minimum score. 100 is the maximum score. In QSH45 : 45 questions are asked to the patient. Each question has a score from 1 (worst) to 5 (best score). The QSH45 score is divided in 8 subscales. The 45 questions are placed equally in the 8 subscales. the total score (QSH45) is the average of the score of the 8 subscales.
Clavien score postoperative month 1
The therapy used to correct a specific complication in the basis of this classification on order to rank a complication in an objective and reproducible manner. It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V). Grade I is the minimum value of the score. Grade V is the maximum value of the score corresponding to the death of a patient.
CCI score
The CCI calculator is an online tool to support the assessment of patients' overall morbidity. The comprehensive complication index (CCI) is based on the complication grading by Clavien-Dindo Classification and implements every occured complication after an intervention. The overall morbidity is reflected on a scale from 0 (no complication) to 100 (death).
Hospital length of stay
the interval between admission to the emergency department and discharge from the ward.
Cumulative length of stay
total number of days of hospitalization related to ASBO

Full Information

First Posted
February 21, 2019
Last Updated
May 9, 2023
Sponsor
Centre Hospitalier Universitaire, Amiens
Collaborators
Centre Hospitalier de Beauvais, Centre Hospitalier Universitaire de Rouen, University Hospital, Caen, University Hospital, Lille, Groupe Hospitalier Pitie-Salpetriere, Centre Hospitalier Universitaire Dijon, University Hospital, Limoges, Saint Antoine University Hospital, University Hospital, Clermont-Ferrand, Hôpital Cochin, University Hospital, Toulouse, Centre Hospitalier de PAU, Hopital Lariboisière, Tourcoing Hospital, Central Hospital Saint Quentin
search

1. Study Identification

Unique Protocol Identification Number
NCT03905239
Brief Title
A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction
Acronym
ALPROC
Official Title
Impact of a Procalcitonin-based Algorithm on Quality of Management in Patients With Uncomplicated Adhesion-related Small Bowel Obstruction Assessed by Textbook Outcome: a Multicenter Cluster-randomized Open-label Controlled Trial. (ALPROC)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
August 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire, Amiens
Collaborators
Centre Hospitalier de Beauvais, Centre Hospitalier Universitaire de Rouen, University Hospital, Caen, University Hospital, Lille, Groupe Hospitalier Pitie-Salpetriere, Centre Hospitalier Universitaire Dijon, University Hospital, Limoges, Saint Antoine University Hospital, University Hospital, Clermont-Ferrand, Hôpital Cochin, University Hospital, Toulouse, Centre Hospitalier de PAU, Hopital Lariboisière, Tourcoing Hospital, Central Hospital Saint Quentin

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Adhesion-related small bowel obstruction is a common digestive emergency that can be managed either conservatively or surgically. However, the choice between these two approaches can be difficult due to the absence of specific signs. The objective of this study is to evaluate the clinical impact of a procalcitonin-based algorithm.
Detailed Description
Acute adhesion-related small bowel obstruction (ASBO) is a common digestive emergency accounting for 1% to 3% of all digestive emergencies. It is associated with a mortality rate of between 2% and 8%, although this figure may be as high as 25% when surgical treatment is delayed. In 2013, the World Society of Emergency Surgery's working group on ASBO suggested two distinct approaches for the management of acute ASBO. Conservative management includes the use of a nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 24 to 72 hours or surgical management. However, the efficacy of conservative management in this setting is a subject of debate, as it might delay the decision to perform surgery and increase the frequency of bowel resection (e.g. in the presence of bowel necrosis) or, in contrast, prompt an excessive number of unnecessary laparotomies. The efficacy of water-soluble contrast medium in this setting is also subject to debate, as data from a recent randomized clinical trial including 242 patients (ABOD study) combined with a meta-analysis in 2015 including 990 patients failed to demonstrate any value of gastrografin to reduce the surgery rate and length of stay. Three years ago, our team proposed the use of a marker of bacterial infection and bowel ischemia, procalcitonin (PCT), to help distinguish patients in whom conservative management is likely to be successful from those in whom surgical management was mandatory. Cutoffs of 0.2 µg/L (for failure of conservative management ) and 0.6 µg/L (for need for surgery) accurately identified more than 80% of patients. These cutoffs and data were confirmed in a second independent cohort, and were then used to propose an algorithm for the management of patients with ASBO. In this single-center, retrospective , case-control study, the investigators showed that introduction of this algorithm into patient management reduced i/ the time to surgery with no increase of the surgical management rate; ii/ the length of stay (with a 2-day difference). The investigators propose the hypothesis that introduction of the PCT-based algorithm improves the quality of management of patients with ASBO.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Bowel Obstruction
Keywords
algorithm, procalcitonin, small bowel obstruction

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
414 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
algorithm arm
Arm Type
Experimental
Arm Description
Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
Arm Title
no algorithm arm
Arm Type
No Intervention
Arm Description
Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
Intervention Type
Diagnostic Test
Intervention Name(s)
algorithm
Intervention Description
clinical examination and procalcitonin assessment
Primary Outcome Measure Information:
Title
proportion of patients achieving textbook outcome
Description
textbook outcome is defined as patients either correctly operated (ischemia confirmed at operation ± resection) or correctly managed conservatively (no need for unplanned surgery) with no major postoperative complications (Clavien-Dindo≥3) and a medical length of stay<5 days (defined as the time at which the patient is medically eligible for discharge), with no postoperative consultation, rehospitalisation and reoperation within 90 days after randomization.
Time Frame
within 90 days after randomization.
Secondary Outcome Measure Information:
Title
1-, 3-, 6-, 9-, 12-month recurrence rates
Description
a new episode of adhesion-related small bowel obstruction.
Time Frame
within 12 postoperative months
Title
QSH45 (questionnaire for satisfaction of hospitalized patients) score evaluating patient satisfaction at postoperative month 1
Description
Evaluation of patient satisfaction at postoperative month 1. Values of scores are between 0 and 100. 0 is the minimum score. 100 is the maximum score. In QSH45 : 45 questions are asked to the patient. Each question has a score from 1 (worst) to 5 (best score). The QSH45 score is divided in 8 subscales. The 45 questions are placed equally in the 8 subscales. the total score (QSH45) is the average of the score of the 8 subscales.
Time Frame
postoperative month 1
Title
Clavien score postoperative month 1
Description
The therapy used to correct a specific complication in the basis of this classification on order to rank a complication in an objective and reproducible manner. It consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V). Grade I is the minimum value of the score. Grade V is the maximum value of the score corresponding to the death of a patient.
Time Frame
postoperative month 1
Title
CCI score
Description
The CCI calculator is an online tool to support the assessment of patients' overall morbidity. The comprehensive complication index (CCI) is based on the complication grading by Clavien-Dindo Classification and implements every occured complication after an intervention. The overall morbidity is reflected on a scale from 0 (no complication) to 100 (death).
Time Frame
postoperative month 1
Title
Hospital length of stay
Description
the interval between admission to the emergency department and discharge from the ward.
Time Frame
postoperative month 12
Title
Cumulative length of stay
Description
total number of days of hospitalization related to ASBO
Time Frame
postoperative month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Uncomplicated acute adhesion-related small bowel obstruction (ASBO) Adults Patients able to express consent Signed written informed consent form Covered by national health insurance Exclusion Criteria: Disease-related criteria: Large bowel obstruction No previous abdominal surgery Signs of peritonitis or strangulation requiring emergency surgery) Obstruction within 4 weeks following previous surgery Ongoing or history of bowel cancer Ongoing or in history of inflammatory bowel disease History of abdominal radiotherapy Active infection Contraindication to contrast-enhanced CT scan Minors Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision) Pregnancy or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Marc Regimbeau, Pr
Phone
(33) 322 088 897
Email
regimbeau.jean-marc@chu-amiens.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Marc Regimbeau, Pr
Organizational Affiliation
CHU Amiens
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amiens Universitary Hospital
City
Amiens
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
jean marc Regimbeau, MD, PhD
Phone
+33 3 22 08 89 05
Email
regimbeau.jean-marc@chu-amiens.fr

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35236281
Citation
Sabbagh C, Mauvais F, Tuech JJ, Tresallet C, Ortega-Debalon P, Mathonnet M, Lefevre JH, Lakkis Z, Fuks D, Muscari F, Dron B, Couderc P, Alves A, Regimbeau JM. Impact of a procalcitonin-based algorithm on the quality of management of patients with uncomplicated adhesion-related small bowel obstruction assessed by a textbook outcome: a multicenter cluster-randomized open-label controlled trial. BMC Gastroenterol. 2022 Mar 2;22(1):90. doi: 10.1186/s12876-022-02144-w.
Results Reference
derived

Learn more about this trial

A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction

We'll reach out to this number within 24 hrs